National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms
Authors
Affiliations
Objective: To better describe the real-world use of active surveillance. Active surveillance is a preferred management option for low-risk prostate cancer, yet its use outside of high-volume institutions is poorly understood. We created multiple claims-based algorithms, validated them using a robust clinical registry, and applied them to Medicare claims to describe national utilization.
Materials And Methods: We identified men with prostate cancer from 2012-2014 in a 100% sample of Michigan Medicare data and linked them with the Michigan Urologic Surgery Improvement Collaborative (MUSIC) registry. Using MUSIC treatment assignment as the standard, we determined the performance of 8 claims-based algorithms to identify men on active surveillance. We selected 3 algorithms (the most sensitive, the most specific, and a balanced algorithm incorporating age and comorbidity) and applied them to a 20% national Medicare sample to describe national trends.
Results: We identified 1186 men with incident prostate cancer and completely linked data. Eight algorithms were tested with sensitivity ranging from 23.5% to 88.2% and specificity ranging from 93.5% to 99.1%. We found that the use of surveillance for men with incident prostate cancer increased from 2007 to 2014, nationally. However, among all men in the population, there was a large decrease in the rate of prostate cancer diagnosis and an increased or stable rate in the use of active surveillance, depending on the algorithm used. Less than 25% of men on active surveillance underwent a confirmatory prostate biopsy.
Conclusion: We describe the performance of claims-based algorithms to identify active surveillance.
Srivastava A, Liu X, Maganty A, Kaufman S, Shay A, Oerline M Cancer. 2024; 131(1):e35633.
PMID: 39501423 PMC: 11734219. DOI: 10.1002/cncr.35633.
Subramanian L, Hawley S, Skolarus T, Rankin A, Fetters M, Witzke K Cancer Med. 2023; 13(1):e6847.
PMID: 38151901 PMC: 10807559. DOI: 10.1002/cam4.6847.
Hu S, Chang C, Snyder J, Deshmukh V, Newman M, Date A JCO Clin Cancer Inform. 2023; 7:e2300083.
PMID: 37988640 PMC: 10681553. DOI: 10.1200/CCI.23.00083.
Maganty A, Kaufman S, Oerline M, Faraj K, Caram M, Shahinian V Urol Pract. 2023; 11(1):207-214.
PMID: 37748132 PMC: 10842494. DOI: 10.1097/UPJ.0000000000000463.
Spratte B, Tan H, Zambrano I, Basak R, Filson C, Jacobs B Urol Oncol. 2023; 41(7):323.e17-323.e25.
PMID: 37149430 PMC: 11228925. DOI: 10.1016/j.urolonc.2023.04.006.